Warning Letter Close-Outs – May 2022
The US FDA released three close-out letters last month, publicly resolving warning letters issued to companies based in Germany, Sweden, and Seattle, WA.
You may also be interested in...
The US Food and Drug Administration and the Veterans Health Administration are partnering to create tools that can help novel technology reach patients more quickly and easily.
The US FDA has approved additional indications for Thermo Fisher Scientific’s Oncomine Dx Target, allowing the companion diagnostic to be used to detect more varieties of lung and thyroid cancer.
Committee leaders in the US Congress have agreed on a stripped-down path to user fee reauthorization, which will not include FDA oversight of diagnostic tests.